Market closedNon-fractional
Bionano Genomics/BNGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Bionano Genomics
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Ticker
BNGO
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
San Diego, United States
Employees
344
Website
www.bionano.com
Bionano Genomics Metrics
BasicAdvanced
$39M
Market cap
-
P/E ratio
-$5.71
EPS
2.41
Beta
-
Dividend rate
Price and volume
Market cap
$39M
Beta
2.41
Financial strength
Current ratio
1.463
Quick ratio
0.626
Long term debt to equity
7.648
Total debt to equity
45.752
Interest coverage (TTM)
-24.99%
Management effectiveness
Return on assets (TTM)
-35.84%
Return on equity (TTM)
-144.33%
Valuation
Price to revenue (TTM)
0.606
Price to book
0.4
Price to tangible book (TTM)
0.64
Price to free cash flow (TTM)
-0.186
Growth
Revenue change (TTM)
26.93%
Earnings per share change (TTM)
19.89%
3-year revenue growth
52.65%
3-year earnings per share growth
31.45%
What the Analysts think about Bionano Genomics
Analyst Ratings
Majority rating from 4 analysts.
Bionano Genomics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$8.7M
-18.69%
Net income
-$31M
-28.31%
Profit margin
-360.91%
-11.83%
Bionano Genomics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q1 24
Q2 24
Actual
-$1.24
-$3.22
-$0.51
-
Expected
-$1.03
-$0.97
-$0.65
-$0.42
Surprise
20.00%
231.96%
-20.93%
-
Bionano Genomics News
AllArticlesVideos
Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewsWire·1 day ago
Scientific Presentations Highlight OGM's Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations
GlobeNewsWire·4 days ago
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bionano Genomics stock?
Bionano Genomics (BNGO) has a market cap of $39M as of July 06, 2024.
What is the P/E ratio for Bionano Genomics stock?
The price to earnings (P/E) ratio for Bionano Genomics (BNGO) stock is 0 as of July 06, 2024.
Does Bionano Genomics stock pay dividends?
No, Bionano Genomics (BNGO) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Bionano Genomics dividend payment date?
Bionano Genomics (BNGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bionano Genomics?
Bionano Genomics (BNGO) has a beta rating of 2.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Bionano Genomics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.